Screening for chlamydia trachomatis and neisseria gonorrhoeae during pregnancy project protocol
The purpose of this HTA is to address the policy question through an assessment of the clinical effectiveness and safety, and cost-effectiveness, and patients', partners', and health care providers' perspectives and experiences regarding the screening of pregnant persons for CT and GC...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2018, February 2018
|
| Series: | CADTH health technology assessment report
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The purpose of this HTA is to address the policy question through an assessment of the clinical effectiveness and safety, and cost-effectiveness, and patients', partners', and health care providers' perspectives and experiences regarding the screening of pregnant persons for CT and GC. An analytic framework for the HTA can be found in Appendix 1 |
|---|---|
| Item Description: | "PROSPERO Registration Number: CRD42018087016 |
| Physical Description: | 1 PDF file (40 pages) illustrations |